Clinical Trial Detail

NCT ID NCT03767348
Title Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Replimune Inc.
Indications

Merkel cell carcinoma

Advanced Solid Tumor

basal cell carcinoma

urinary bladder cancer

skin squamous cell carcinoma

skin cancer

melanoma

basosquamous carcinoma

Therapies

Nivolumab + RP1

RP1

Age Groups: senior adult

Additional content available in CKB BOOST